Affinity Asset Advisors’s Viridian Therapeutics VRDN Stock Holding History

Affinity Asset Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.59M	Hold	250,000	–	–	0.21%	81
2026 Q1	$4.89M	Hold	250,000	–	–	0.25%	69
2025 Q4	$7.78M	Hold	250,000	–	–	0.44%	52
2025 Q3	$5.39M	Sell	250,000 -140,000	-36%	-$2.53M	0.47%	49
2025 Q2	$5.45M	Hold	390,000	–	–	0.74%	38
2025 Q1	$5.26M	Buy	390,000 +230,386	+144%	+$3.92M	0.5%	40
2024 Q4	$3.06M	Sell	159,614 -365,386	-70%	-$7.94M	0.41%	50
2024 Q3	$11.9M	Buy	525,000 +375,000	+250%	+$6.13M	1.63%	22
2024 Q2	$1.95M	Buy	+150,000	New	+$2.08M	0.23%	64
2024 Q1	–	Sell	-50,000	Closed	-$1.09M	–	117
2023 Q4	$1.09M	Buy	+50,000	New	+$789K	0.2%	68
2022 Q3	–	Sell	-20,660	Closed	-$239K	–	81
2022 Q2	$239K	Sell	20,660 -29,340	-59%	-$394K	0.1%	51
2022 Q1	$925K	Buy	+50,000	New	+$961K	0.15%	48

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Affinity Asset Advisors's VRDN Position: Q2 2026 in Review

Affinity Asset Advisors held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 250,000 shares worth $4.59M. The position accounts for 0.21% of the portfolio, ranked #81.

Affinity Asset Advisors first reported a position in VRDN in Q1 2022 and has held it in 12 quarters since. The position peaked at $11.9M in Q3 2024. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Affinity Asset Advisors held 250,000 shares of Viridian Therapeutics worth $4.59M as of Q2 2026.
Affinity Asset Advisors left its Viridian Therapeutics share count unchanged in Q2 2026.
Viridian Therapeutics made up 0.21% of Affinity Asset Advisors's portfolio in Q2 2026, its #81 holding.
Affinity Asset Advisors first reported a position in Viridian Therapeutics in Q1 2022 and has held it in 12 quarters since.
Affinity Asset Advisors's Viridian Therapeutics position peaked at $11.9M in Q3 2024.
212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.